Parkman Healthcare Partners LLC

STAMFORD, CT · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.11B2026 Q3
Positions91
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.32.4%

Parkman Healthcare Partners LLC reported 91 positions worth $1.11B as of September 30, 2026 (13F filed November 16, 2026). Largest holding: PTCT (4.1%). Biggest move: new buy SRRK ($26.1M).

10 / 91 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 PTCTPTC Therapeutics$45.4M4.09%700,393——-5.9%
▸ 2 LLYEli Lilly$44.1M3.97%38,119——+23.7%
▸ 3 MBXMBX Biosciences$42.0M3.78%716,542——-9.4%
▸ 4 IQVIqvia$39.0M3.52%145,221——-1.5%
▸ 5 DXCMDexcom$37.7M3.40%437,034——-5.4%
▸ 6 INBXInhibrx Biosciences$36.1M3.25%360,260——-22.4%
▸ 7 VRDNViridian Therapeutics$34.5M3.11%1,674,834——+49.9%
▸ 8 URGNUroGen Pharma$30.5M2.75%750,202——-30.8%
▸ 9 SRRKScholar Rock$26.1M2.35%540,000——-7.8%
▸ 10 CVSCVS Health$24.5M2.21%286,286——+3.4%

Pro Feature

The remaining 81 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Parkman Healthcare Partners LLC hold as of Q3 2026?

Parkman Healthcare Partners LLC reported 91 positions worth $1.11B in its Q3 2026 13F filing. Largest positions: PTCT (4.1%), LLY (4.0%), MBX (3.8%), IQV (3.5%) and DXCM (3.4%).

What did Parkman Healthcare Partners LLC buy in Q3 2026?

New positions: SRRK, CRL, KOD, ABT and WST (27 in all). Added to: URGN, PTCT, ANRO, IQV and INBX (31 in all).

What did Parkman Healthcare Partners LLC sell in Q3 2026?

Reduced: EWTX, PODD, CVS, THC and DXCM (32 in all). Sold out entirely: SYK, ZBH, BCRX, QURE and AMRX (13 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.